QBIO News and Press, Q BioMed Inc From 03/19/19

Q BioMed ( OTCQB:QBIO ) and its technology partner Mannin Research has entered into a research collaboration with the Biointerfaces Institute at McMaster University in Ontario, Canada to develop a GDF15 biomarker diagnostic kit for monitoring glaucoma severity and progression. More ...

Enabling technology to more effectively manage glaucoma progression and patient treatment Serves unmet need - Currently no single examination or diagnostic test is able to accurately predict disease progression Simple diagnostic test that can be performed at a physician's office w...

NEW YORK , March 13, 2019 /PRNewswire/ --  OTC Markets Group Inc . (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today unveiled the list of OTCQX® Best Market and OTCQB® Venture Market company presentations at the 31 st Annual ROTH Con...

BALTIMORE, Maryland , March 12, 2019 /PRNewswire/ -- Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has released a new Company Spotlight article on high profile biomedical company Q Biomed Inc. (OTCQB:...

NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Q BioMed Inc. ( QBIO ), a commercial stage biotechnology acceleration development company, is pleased to announce it has exercised its option to exclusively license GDF15, a diagnostic marker for determining the severity of glaucoma using the e...

New York, New York--(Newsfile Corp. - March 11, 2019) -  Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce it has exercised its option to exclusively license GDF15, a diagnostic marker for determining the severity o...

NEW YORK, NY / ACCESSWIRE / March 7, 2019 / Q BioMed (OTCQB:QBIO), has been getting attention from biotech investors and pharma industry publications for its "upside down" biotech business model. The company expects to continue making strides in developing their product offerings and appears...

New York, New York--(Newsfile Corp. - February 26, 2019) - Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, today announced that in the February issue of DDNews , journalists conducted an interview with Q BioMed CEO Dennis Corin, focused on the mechanism of action, develop...

NEW YORK, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Q BioMed Inc. (OTCQB: QBIO ), a biotechnology acceleration company, announces multiple interviews with the company’s CEO, Denis Corin, and the Q BioMed team are now available. An exclusive video interview with Chairman and CEO Deni...

NEW YORK, NY / ACCESSWIRE / February 8, 2019 / Q BioMed (OTCQB: QBIO) has announced that it is bringing innovation to the treatment of Glaucoma- the the leading cause of irreversible blindness globally. The illness often remains undetected long after significant vision loss has already occur...